Head-to-head · Value Score
CoreAge Rx vs Goldspan Health
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Goldspan Health a 71. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameGoldspan Health
#218 · Grade C · Watch List
Est. first month
$229 every 28 days, month-to-month (thirteen charges a year, not twelve)
Save ~83% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 71 — an est. $99/mo first month, with no teaser step-up baked in. Goldspan Health isn't out of it: Shoppers who want a flat single-tier price with no plan ladder to decode, and who will do the thirteen-charge arithmetic before comparing it with a calendar-month rate.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Goldspan Health |
|---|---|---|
| Value Score | 93 (A+) | 71 (C) |
| Est. first month | $99/mo | $229 every 28 days, month-to-month (thirteen charges a year, not twelve) |
| Save vs brand-name | ~89% | ~83% |
| Semaglutide | $99/mo | $229 every 28 days, month-to-month (thirteen charges a year, not twelve) |
| Tirzepatide | $149/mo | $299 every 28 days, month-to-month (thirteen charges a year, not twelve) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | All 50 states claimed, no list published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Goldspan Health
A single-plan desk with no commitment tiers and no introductory month, selling compounded semaglutide at $229 and tirzepatide at $299 — priced "/month" in the hero and billed every 28 days on the plan card, which is thirteen charges a year.
Why it's a deal
- One plan and one price per product: no three-, six- or twelve-month ladder, no introductory rate, and nothing to lock into — the commitment trap simply is not present
- The catalog is unusually broad and openly priced: injectable and daily sublingual, full dose and low dose, semaglutide and tirzepatide, at $229, $299, $199, $299, $149 and $199 respectively
- The pharmacy class is stated plainly — all therapies dispensed by a pharmacy licensed under section 503A or 503B — which is more than most desks put in writing, even though no pharmacy is named
- Three clinicians are named with their roles and specialties on the storefront that fulfills the orders, and a phone number is published there
- The order timeline tells you when the renewal lands rather than leaving the cadence to be discovered on a card statement, and pausing, delaying or canceling is offered through the portal
The fine print
- A month here is twenty-eight days. The hero says "/month", the plan card says billed every 28 days and the timeline says every four weeks — thirteen charges a year, so the real annual cost is about $230 higher on semaglutide and $300 higher on tirzepatide than the monthly framing implies
- The cancellation promise and the refund policy contradict each other: pause, delay or cancel at any time on one page, all sales final on another, and "once you place an order it cannot be canceled" in the storefront's own terms
- The brand publishes no legal entity, no address and no governing law of its own — the only company details on the transaction belong to the storefront that fulfills it
- No pharmacy is named, and the clinicians named belong to that storefront while the same storefront states it is not a medical practice
- All 50 states is claimed on the homepage while the terms say some therapies are unavailable in certain states, and no list is published either way
- The full-dose sublingual products at $199 and $299 are not linked from the weight-loss page, so the cheapest oral route is reachable only by finding the catalog
- One product page's inclusion list names the wrong molecule — a tirzepatide page describing compounded sublingual semaglutide — which is the kind of copy error that matters on a prescription product
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Goldspan Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.